RA-9

• Description:

  RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER) -stress responses in ovarian cancer cells[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Apoptosis; Deubiquitinase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ra-9.html

• Concentration:

  10mM

• Purity:

  98.57

• Solubility:

  DMSO : 4.17 mg/mL (ultrasonic; warming; heat to 80°C)

• Smiles:

  O=C1/C(CNC/C1=C\C2=CC=C([N+]([O-])=O)C=C2)=C/C3=CC=C([N+]([O-])=O)C=C3

• Molecular Formula:

  C19H15N3O5

• Molecular Weight:

  365.34

• Precautions:

  H302

• References & Citations:

  [1]Coughlin K, et al. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res. 2014;20 (12) :3174-3186.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [919091-63-7]